<DOC>
	<DOCNO>NCT01785810</DOCNO>
	<brief_summary>RATIONALE : Successful allogeneic stem-cell transplantation often limit graft-versus-host disease ( GVHD ) . Migration donor cell tissue play major role GVHD . Drugs block chemokine receptor CCR5 , potentially decrease migration donor cell tissue . Blocking CCR5 allogeneic stem-cell transplantation may therefore reduce rate GVHD . PURPOSE : This study explore efficacy pharmacologic inhibition CCR5 prevention GVHDby administer maraviroc allogeneic stem-cell transplantation reduce intensity conditioning .</brief_summary>
	<brief_title>Phase II Maraviroc GVHD Prevention</brief_title>
	<detailed_description>Detailed Description : PRIMARY OBJECTIVES : To estimate cumulative incidence grade 2-4 acute GVHD day 180 addition maraviroc standard prophylaxis regimen patient hematologic malignancy undergo reduced intensity allogeneic stem-cell transplantation ( RIC SCT ) unrelated donor . SECONDARY OBJECTIVES : 1 . To assess toxicity prolong administration maraviroc patient undergo RIC SCT . 2 . To estimate rate severe ( grade 3-4 ) acute GVHD day 100 180 , grade 2-4 acute GVHD day 100 , organ-specific acute GVHD , chronic GVHD , relapse , infection , non-relapse mortality , use immunosuppressive therapy 1-year survival patient treat maraviroc RIC SCT . 3 . To assess effect treatment maraviroc immune recovery , engraftment donor T-cell chimerism peripheral blood target organ . 4 . To assess effect donor recipient CCR5 genotype incidence acute GVHD patient receive maraviroc part GVHD prophylaxis regimen . OUTLINE : Patients receive standard condition regimen fludarabine busulfan follow peripheral blood stem cell infusion unrelated donor , standard GVHD prophylaxis standard antiviral antifungal prophylaxis . In addition , patient receive maraviroc day -3 d+ 90 . Patients follow 1 year stem-cell infusion .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Patients ≥18 year age hematologic malignancy aplastic anemia primary myelofibrosis , schedule undergo RIC allogeneic SCT peripheral blood stem cell graft unrelated donor , use Flu/Bu condition Tac/MTX GVHD prophylaxis . The following diagnosis include : Acute leukemia AML , ALL acute biphenotypic leukemia . Patients documentation complete remission within 6 week prior transplant . Complete remission define &lt; 5 % blast bone marrow biopsy absence know extramedullary disease . Chronic myelogenous leukemia stage , documentation &lt; 5 % blast bone marrow biopsy within 6 week prior transplant . Myelodysplastic syndrome subtype , documentation &lt; 5 % blast bone marrow biopsy within 6 week prior transplant . Myeloproliferative disorder primary myelofibrosis . Lymphoma All type lymphoma eligible . CLL PLL . Patients meet institutional eligibility criterion allogeneic SCT : Renal function : Serum creatinine ≤2 . Hepatic function : Baseline direct bilirubin , ALT AST low three time upper limit normal . Pulmonary disease : FVC FEV1 ≥ 40 % predict . Cardiac ejection fraction ≥ 40 % . Availability unrelated donor , identify screen NMDP . The donor least 7/8 HLAA , B , C DRB1 match high resolution molecular type meet NMDP eligibility criterion serve peripheral blood stemcell donor . Karnofsky score ≥ 70 % time screening . Capacity understand sign study inform consent form . Negative pregnancy test . Women childbearing potential ( hysterectomy , bilateral oophorectomy bilateral tubal ligation , postmenopausal total cessation menses &gt; 1 year ) must agree use document reliable method ( ) contraception . Men agree use condom study period . Coenrollment clinical trial include experimental GVHD therapy allow . Exclusion Criteria Patients aplastic anemia primary myelofibrosis . Patients marrow fibrosis secondary MDS , AML myeloproliferative disorder primary myelofibrosis eligible . Patients expect available followup institution least 180 day transplant . Prior allogeneic SCT . Uncontrolled bacterial , viral fungal infection . Patients receive maraviroc treatment HIV infection . Patients receive investigational drug GVHD . Coenrollment clinical trial include experimental GVHD therapy allow . Patients prior malignancy exclude unless treat curative intent know free disease least 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>